Skip to main content Help with accessibility Skip to main navigation

All Guidance

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Licensed: Severe active rheumatoid arthritis, including juvenile forms, Wilson's disease (hepatolenticular degeneration) in adults and children (0 to 18 years).

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
BNF chapter: Blood and Nutrition
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2016

The purpose of this guidance is to outline recommendations for prescribing within primary care in Lancashire and South Cumbria. It is intended to provide information on current best practice including providing advice on prescribing situations which are not always clear so as to ensure a consistent approach by primary care prescribers across Lancashire and South Cumbria. All prescribers are encouraged to follow this guide.

Pending
Adopted
Pending
Pending
Adopted
Pending
Adopted
Pending
Date Posted: 29 - March - 2021
BNF chapter: Central nervous system
This guideline provides recommendations on the medical management of adults with neuropathic pain. The outlined treatment strategy is relevant to non-specialist settings.
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 19 - July - 2022
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2018
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2017
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Pending
Pending
Date Posted: 18 - November - 2020
BNF chapter: Infection
Adapted from NICE guideline 112
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Pending
Date Posted: 19 - March - 2021
BNF chapter: Endocrine system

Please note: GPs and other primary care prescribers are under no obligation to act upon the advice issued by a private specialist. If the NHS prescriber receiving the request does not believe they have the competence to initiate or continue the recommended intervention a referral to an appropriate NHS specialist should be made. Patients are entitled to receive additional private care if this is provided separately from NHS care.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2015
BNF chapter: Musculoskeletal system

The purpose of these guidelines is to provide a quick reference guide for use in primary care summarising information on the diagnosis and management of RLS in primary care. This guidance covers the management of RLS in primary care and gives information about when to refer to secondary care. 

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - August - 2019
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2015

To extend life or the time to mechanical ventilation for adult patients with amyotrophic lateral sclerosis (ALS) 1,2, variant of Motor Neurone Disease (MND). Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other forms of MND. Riluzole should only be initiated by a neurological specialist with expertise in the management of MND (as per NICE TA 20, 2001)

It is expected that most patients will be managed by secondary care however this guideline is those patients who need to be managed in community

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2016
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 16 - November - 2021
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2019
BNF chapter: Central nervous system

The purpose of this guidance is to provide clarity on the approval process for the prescribing of the second-generation antipsychotic long-acting injections within Lancashire Care NHS Foundation Trust. 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Licensed – Active, progressive rheumatoid arthritis, progressive juvenile chronic arthritis especially if polyarticular or seropositive.
Unlicensed – skin diseases including pemphigus

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2014
BNF chapter: Blood and Nutrition
**This Guideline is currently under review. For further information please click here**

The purpose of this guidance is to outline recommendations for the prescribing of specialist infant formula milk within primary care in Lancashire and South Cumbria.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2017
BNF chapter: Stoma Appliances

This guidance aims to support primary care in the prescription management process around cost-effective and rational prescribing for continence and stoma products.It is intended for all health care professionals and third party organisations involved in the prescribing, ordering and review of stoma and incontinence products within the Lancashire and South Cumbria Health Economy.

**This Guideline is currently under review. For further information please click here**
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted

Licensed: Rheumatoid arthritis; ulcerative colitis, Crohn’s disease in adults and children
Unlicensed: Sero-negative spondyloarthropathy including psoriatic arthritis and psoriasis.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Not adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

This position statement relates to the use of tapentadol MR for the following indications:

1. As a treatment option for intractable neuropathic pain in non-palliative care patients
2. As a treatment for nonspecific pain